NAVIDEA BIOPHARMACEUTICALS I - COM (NAVB)

CUSIP: 63937X103

Q2 2016 13F Holders as of 30 Jun 2016

Type / Class
Equity / COM
Total 13F shares
26,888,509
Share change
-7,320,718
Total reported value
$14,283,000
Price per share
$0.53
Number of holders
58
Value change
-$4,830,200
Number of buys
27
Number of sells
44

Quarterly Holders Quick Answers

What is CUSIP 63937X103?
CUSIP 63937X103 identifies NAVB - NAVIDEA BIOPHARMACEUTICALS I - COM in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Institutional Holders of NAVIDEA BIOPHARMACEUTICALS I - COM (NAVB) as of Q2 2016

As of 30 Jun 2016, NAVIDEA BIOPHARMACEUTICALS I - COM (NAVB) was held by 58 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 26,888,509 shares. The largest 10 holders included COMMERZBANK AKTIENGESELLSCHAFT /FI, VANGUARD GROUP INC, GOLDMAN SACHS GROUP INC, MILLENNIUM MANAGEMENT LLC, BlackRock Institutional Trust Company, N.A., GEODE CAPITAL MANAGEMENT, LLC, Harel Insurance Investments & Financial Services Ltd., BRIDGEWAY CAPITAL MANAGEMENT INC, Paloma Partners Management Co, and D. E. Shaw & Co., Inc.. This page lists 58 institutional shareholders reporting positions in this security for the Q2 2016 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.